At the news
? BULLISHIMPACT 8/10 8-K filed Apr 13, 2026 at 08:25 ET
Revolution Medicines announced positive topline results from its Phase 3 RASolute 302 trial, showing daraxonrasib significantly improved overall survival and progression-free survival in metastatic pancreatic cancer patients compared to chemotherapy. The company plans to submit the data for regulatory approval, including under a U.S. FDA Priority Voucher.
- Daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40, p < 0.0001) in metastatic pancreatic ductal adenocarcinoma.
- The drug showed statistically significant and clinically meaningful improvements in both progression-free survival and overall survival.
- Daraxonrasib was generally well tolerated with no new safety signals.
- Results are from the first interim analysis and are considered final.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access